Delaware is the US’s go-to venue for pharma patent litigation, but there could be trouble ahead
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Author | Life sciences reporter
@IAM_magazine Bristol Myers Squibb's Henry Hadad on IP and the covid pandemic and why more needs to be done on 101 reform… https://t.co/dp4RDjKBTG Read more
@IAM_magazine After PTAB upholds key patent, Moderna set to face infringement battle over its covid-19 vaccine mRNA-1273:… https://t.co/8kthk3cE58 Read more
@IAM_magazine Chinese tech companies are under pressure like never before in India, and the patent litigation keeps coming… https://t.co/TkwjY68Ywj Read more
@IAM_magazine RT @McDermottLaw: Join Jed Gordon, Head of the Firm’s IP Transactions Practice, & @IAM_magazine @ #IPBCConnect 2020 for the “Proactive IP… Read more